APO RESEARCH · REPORT
GLP-1 Agonists for the Treatment of both Diabetes and Obesity
Selected research
Industry Growth & Trends
Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global GLP-1 Agonists for the Treatment of both Diabetes and Obesity market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for GLP-1 Agonists for the Treatment of both Diabetes and Obesity is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for GLP-1 Agonists for the Treatment of both Diabetes and Obesity is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for GLP-1 Agonists for the Treatment of both Diabetes and Obesity is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the GLP-1 Agonists for the Treatment of both Diabetes and Obesity market include Novo Nordisk and Eli Lilly among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global GLP-1 Agonists for the Treatment of both Diabetes and Obesity market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The GLP-1 Agonists for the Treatment of both Diabetes and Obesity market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global GLP-1 Agonists for the Treatment of both Diabetes and Obesity market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to GLP-1 Agonists for the Treatment of both Diabetes and Obesity.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global GLP-1 Agonists for the Treatment of both Diabetes and Obesity market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market by Company
Novo Nordisk
Eli Lilly
GLP-1 Agonists for the Treatment of both Diabetes and Obesity Segment by Type
Tirzepatide
Semaglutide
Liraglutide
GLP-1 Agonists for the Treatment of both Diabetes and Obesity Segment by Application
Retail Pharmacies
Hospital and Clinic
Other
GLP-1 Agonists for the Treatment of both Diabetes and Obesity Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global GLP-1 Agonists for the Treatment of both Diabetes and Obesity market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of GLP-1 Agonists for the Treatment of both Diabetes and Obesity and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of GLP-1 Agonists for the Treatment of both Diabetes and Obesity.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of GLP-1 Agonists for the Treatment of both Diabetes and Obesity companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Tirzepatide
- Semaglutide
- Liraglutide
Applications
- Retail Pharmacies
- Hospital and Clinic
- Other
Companies covered
- Novo Nordisk
- Eli Lilly
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Region (2021-2032)
- 1.4.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Region (2021-2026)
- 1.4.2 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Region (2027-2032)
- 1.5 Key Regions GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size (2021-2032)
- 1.5.1 North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth Rate (2021-2032)
- 1.5.2 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth Rate (2021-2032)
- 1.5.4 South America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth Rate (2021-2032)
2 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market by Type
- 2.1 Type Introduction
- 2.1.1 Tirzepatide
- 2.1.2 Semaglutide
- 2.1.3 Liraglutide
- 2.2 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Type
- 2.2.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Overview by Type (2021-2032)
- 2.2.2 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Forecasted by Type (2027-2032)
- 2.3 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Regions
- 2.3.1 North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Breakdown by Type (2021-2026)
3 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market by Application
- 3.1 Type Introduction
- 3.1.1 Retail Pharmacies
- 3.1.2 Hospital and Clinic
- 3.1.3 Other
- 3.2 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Application
- 3.2.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Overview by Application (2021-2032)
- 3.2.2 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Forecasted by Application (2027-2032)
- 3.3 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Regions
- 3.3.1 North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Industry Trends
- 4.2 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Industry Drivers
- 4.3 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Industry Opportunities and Challenges
- 4.4 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue (2021-2026)
- 5.2 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Key Company Headquarters & Area Served
- 5.4 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Company, Product Type & Application
- 5.5 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Players Market Share by Revenue in 2025
- 5.6.3 2025 GLP-1 Agonists for the Treatment of both Diabetes and Obesity Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Novo Nordisk
- 6.1.1 Novo Nordisk Company Information
- 6.1.2 Novo Nordisk Business Overview
- 6.1.3 Novo Nordisk GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Novo Nordisk GLP-1 Agonists for the Treatment of both Diabetes and Obesity Product Portfolio
- 6.1.5 Novo Nordisk Recent Developments
- 6.2 Eli Lilly
- 6.2.1 Eli Lilly Company Information
- 6.2.2 Eli Lilly Business Overview
- 6.2.3 Eli Lilly GLP-1 Agonists for the Treatment of both Diabetes and Obesity Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Eli Lilly GLP-1 Agonists for the Treatment of both Diabetes and Obesity Product Portfolio
- 6.2.5 Eli Lilly Recent Developments
7 North America
- 7.1 North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2021-2026)
- 7.3 North America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2021-2026)
- 8.3 Europe GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2021-2026)
- 9.3 Asia-Pacific GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2021-2026)
- 10.3 South America GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size by Country (2021-2026)
- 11.3 Middle East & Africa GLP-1 Agonists for the Treatment of both Diabetes and Obesity Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst